LCEP2

Across TCGA pan-cancer cohorts, LCEP2 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated LCEP2 data layer.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher LCEP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LCEP2 expression acts as an unfavorable survival marker.

ESCA, STAD, and KIRP are the cancer types where LCEP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Tertile	III,IV	0.074	0.574	<.001	90	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	63	view →
KIRP	DFS	Tertile	II,III,IV	0.191	0.781	<.001	36	view →
SARC	OS	Tertile	All	0.108	0.839	<.001	36	view →
LGG	DFS	Tertile	All	0.273	0.757	.006	27	view →
SKCM	OS	Tertile	IV	0.415	0.861	.014	24	view →
LIHC	OS	Tertile	II,III,IV	0.128	0.617	.037	18	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LCEP2–ESCA (OS)

Open the ESCA breakdown →